Furthermore, to establish whether HER-3 may represent a suitable target for targeted therapy in CRC, we evaluate in vitro cell-killing activity of EV20/MMAF, a potent and specific monomethyl auristatin F-based anti-HER-3 ADC developed by our group [19–21]. This evidence concerns the gene ERBB3 and colorectal carcinoma.